AstraZeneca PLC ADR closed 23.70% below its 52-week high of $87.68, which the company reached on August 30th.

Astra said a trial of its Enhertu treatment showed the drug demonstrated a 'highly statistically significant' improvement on ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Both men and women are now just as likely to confirm gender pay gap figures, as responsibility passes from CEOs to HR ...

The partnership, now in its second year, features a limited-edition T-shirt and the Body Check Cup in order to encourage more cancer screenings.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic ...

AstraZeneca AZN will report its first-quarter 2025 earnings on April 29, before market open. The Zacks Consensus Estimate for ...